Featured Content

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Second Opinion from Cancer Center Yielded Valuable Information for Breast Cancer Management

A change in diagnosis was often the result of review by a multidisciplinary tumor board at the NCI-designated cancer center.

The Immune Landscape in Metastatic Breast Cancer Is "More Inert"

Researchers compared the immune microenvironments of primary tumors with those at sites of metastases.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

More Features>>>

Breast Cancer Resources

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs